Microba Life SciencesASX:MAP -2.50% Net Current Asset Value is A$0.00 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Microba Life Sciences ranks worse than 50.51% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Microba Life Sciences's net current asset value per share for the quarter that ended in Dec. 2025 was A$0.00.
The historical rank and industry rank for Microba Life Sciences's Net Current Asset Value or its related term are showing as below:
ASX:MAP'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.89 Med: 3.15 Max: 9.75
Current: 3.9
During the past 4 years, the highest Price-to-Net-Current-Asset-Value Ratio of Microba Life Sciences was 9.75. The lowest was 1.89. And the median was 3.15.
ASX:MAP's Price-to-Net-Current-Asset-Value is ranked worse than 50.51% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.9
vs ASX:MAP: 3.90
Microba Life Sciences (ASX:MAP) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Microba Life Sciences Net Current Asset Value Related Terms
Microba Life Sciences Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Microba Life Sciences's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microba Life Sciences Net Current Asset Value Chart
ASX:MAP vs TMO, DHR, IDXX: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, Microba Life Sciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microba Life Sciences Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Microba Life Sciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Microba Life Sciences's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of A$0.00 mean?
Microba Life Sciences (ASX:MAP) has a Net Current Asset Value of A$0.00 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Microba Life Sciences and its competitors. Over the past decade, Microba Life Sciences' Net Current Asset Value has ranged from 1.89 to 9.75. According to the industry distribution chart, Microba Life Sciences ranks #50 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 50.5%.
Is Microba Life Sciences' Net Current Asset Value too high?
Microba Life Sciences' current Net Current Asset Value is A$0.00. Over the past 10 years, this metric has ranged from a low of 1.89 to a high of 9.75. Based on the distribution chart, Microba Life Sciences ranks #50 out of 99 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Microba Life Sciences' Net Current Asset Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Microba Life Sciences ranks #50 out of 99 companies for Net Current Asset Value. This places Microba Life Sciences in the lower half of its industry. The industry median Net Current Asset Value is 3.90. Historically, Microba Life Sciences' own Net Current Asset Value has ranged from 1.89 to 9.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 3.90, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Microba Life Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microba Life Sciences's current Net Current Asset Value is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Microba Life Sciences (ASX:MAP) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.25, compared to a current price of A$0.04 — trading 84.4% below its estimated fair value. The current Net Current Asset Value is A$0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Microba Life Sciences (ASX:MAP), the current Net Current Asset Value is A$0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MAP has been successfully added to your 